Vikrant Vijay
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Staff Fellow (Pharmacologist)
Also affiliated: United States Food and Drug Administration (2013–2026); Center for Drug Evaluation and Research (2020); North Carolina State University (2007–2009); Annamalai University (2011); Yashoda Hospital (2023); Advanced Energy Materials (United States) (2015); Youth Development (2025); Joint Research Center (2015); RMIT University (2015)
Staff Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Vikrant Vijay's research focuses on understanding and predicting drug-induced toxicities, particularly cardiotoxicity. His work investigates the molecular mechanisms underlying these adverse effects, employing techniques such as gene expression profiling and metabolomics. A significant portion of his research has examined the cardiotoxic effects of doxorubicin, an antineoplastic antibiotic, in mouse models. He has explored delayed-onset cardiotoxicity and the potential role of specific pathways, like the apelin-APJ pathway, in sex-related differential toxicity. Vijay has also identified circulating microRNAs as potential early biomarkers for chronic cardiotoxicity. His research extends to the development of frameworks for integrating transcriptomics and metabolomics data in regulatory toxicology and has explored metabolomics for identifying biomarkers in COVID-19 patient plasma. Collaborations include work with researchers from the National Center for Toxicological Research and the University of Arkansas for Medical Sciences.
Metrics
- h-index: 16
- Publications: 45
- Citations: 1,203
Selected Publications
-
Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)
-
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)
-
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)
-
MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity (2022)
-
Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice (2021)
-
Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology (2021)
-
Gene expression profiling in dorsolateral prostates of prepubertal and adult Sprague-Dawley rats dosed with estradiol benzoate, estradiol, and testosterone (2020)
-
Hepatic Transcript Profiles of Cytochrome P450 Genes Predict Sex Differences in Drug Metabolism (2020)
-
Rebuttal to the comments by Dr. Yan Xu on the article “Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone” (2019)
-
Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F1 mice (2018)
-
Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone (2018)
-
In Vitro Modulation of Redox and Metabolism Interplay at the Brain Vascular Endothelium: Genomic and Proteomic Profiles of Sulforaphane Activity (2018)
-
Sex and age differences in the expression of liver microRNAs during the life span of F344 rats (2017)
Collaboration Network
Top Collaborators
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
- Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
Similar Researchers
Based on overlapping research topics